Plus Therapeutics reported a quarterly loss of $1.05 per share, wider than the Zacks Consensus Estimate of a $0.95 loss. The company also posted a much smaller loss than a year ago, when EPS was -$14, but the latest result still missed expectations. The update is negative for near-term sentiment and could pressure PSTV shares modestly.
Plus Therapeutics reported a quarterly loss of $1.05 per share, wider than the Zacks Consensus Estimate of a $0.95 loss. The company also posted a much smaller loss than a year ago, when EPS was -$14, but the latest result still missed expectations. The update is negative for near-term sentiment and could pressure PSTV shares modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.40
Ticker Sentiment
